Eric A Dietrich
· Clinical Associate ProfessorVerifiedUniversity of Florida · General Internal Medicine
Active 1969–2026
About
Eric A Dietrich, Pharm.D., BCACP, CPC-A, CEMC, CPB, is a Clinical Associate Professor within the Department of Pharmacy Education and Practice at the University of Florida. His work involves managing an Anticoagulation Clinic at UF Health Internal Medicine at Kanapaha, where he monitors warfarin and DOACs, as well as overseeing a multidisciplinary transitions of care clinic for patients with recent acute myocardial infarction housed within UF Health Shands Cardiology service. His research interests include interventions aimed at reducing anticoagulation, hypertension, cardiovascular disease, and pharmacy billing and reimbursement for clinical services in collaborative clinical environments. Dr. Dietrich’s teaching focuses on anticoagulation, cardiovascular disease, osteoporosis, pharmacy billing, and ambulatory care. He is a member of the American Academy of Professional Coders and the American College of Clinical Pharmacy.
Research topics
- Medicine
- Internal medicine
- Cardiology
- Family medicine
- Intensive care medicine
- Genetics
- Medical physics
Selected publications
Shared visits vs incident-to billing for pharmacy services
Journal of Managed Care & Specialty Pharmacy · 2026-03-26
articleOpen access1st authorCorrespondingPharmacists deliver high-value cognitive services in the ambulatory care setting; however, lack of provider recognition under the Social Security Act restricts their ability to independently deliver billable clinical services and access reimbursement through national payers such as Medicare Part B. This often raises the question of whether the collaborative efforts of a pharmacist and a billing provider (eg, physician) during a patient encounter can be combined as a "shared visit" to bill for a higher level of service (LOS). However, a distinction must be made between shared visits and "incident-to" billing. In an incident-to model, in which a pharmacist sees the patient alone under billing provider supervision, the service can only be billed at the lowest level, 99211, according to Medicare as of 2026. Even when both a pharmacist and billing provider see the patient and contribute to the visit, the pharmacist's documentation cannot be used to determine the LOS because they are not a recognized billing provider; only the billing provider's documented work counts for billing purposes. However, this should not deter collaboration between pharmacists and other health care providers given the clinical benefits of team-based care. With evolving billing requirements tied to documentation of the billing provider, opportunities remain to establish sustainable collaborative care models despite limitations in leveraging combined pharmacist-billing provider documentation to increase LOS through a shared visit model.
BMJ Open Quality · 2026-01-01
articleOpen accessBackground Anticoagulation for stroke prevention is often recommended for patients with non-valvular atrial fibrillation (AF), yet many eligible patients do not receive guideline-concordant anticoagulation. Prior quality improvement (QI) initiatives to improve anticoagulation in AF have had mixed results. Methods Preventing Preventable Strokes: Scalability used a triad of interventions to increase the number of eligible patients with AF receiving guideline-concordant anticoagulation, including (1) a best practice alert integrated with the electronic health record, (2) clinician education and (3) patient communication about the anticoagulation therapy that encouraged shared decision-making with clinicians. These interventions were conducted in primary care and cardiology outpatient clinics at (University of Florida Health). Patient-level data were collected during a 6-month intervention period and compared with a 6-month historical control period. Generalised estimating equations with a logistic link were used to estimate the odds of anticoagulant use, adjusting for demographic and clinical characteristics. Results A total of 3274 individuals were included during the intervention period and 3200 during the preintervention period. The average anticoagulation rate increased from 75.7% to 79.2% across the two periods. In the fully adjusted model, patients in the intervention period had significantly higher odds of anticoagulant use compared with the preintervention period (adjusted OR (aOR) 1.13, 95% CI 1.05 to 1.21, p=0.0007). MyChart activation (aOR 1.38, 95% CI 1.19 to 1.61, p<0.0001) was also associated with increased anticoagulant use. Older age and higher CHA 2 DS 2 -VASc scores were associated with greater odds of anticoagulant use, while higher HAS-BLED scores and care in primary care (rather than cardiology) were associated with lower odds. Conclusions A triad of QI interventions at the practice, clinician and patient levels increased guideline-concordant anticoagulation use among patients with AF in half of the primary care and cardiology clinics in the University of Florida Health system.
Heart Rhythm · 2024-05-01
articleOpen accessValue in Health · 2024-06-01
articleAmerican Journal of Health-System Pharmacy · 2024-02-29
articlePURPOSE: Sacubitril/valsartan (SAC/VAL) or angiotensin receptor blockers (ARBs) are recommended therapy for heart failure with preserved ejection fraction (HFpEF), but little is known about their real-world comparative effectiveness among patients with HFpEF. The objective of this study was to determine the comparative effectiveness of SAC/VAL vs ARBs in preventing HF-related hospitalization or all-cause hospitalization among patients with HFpEF. METHODS: We conducted a cohort study using IBM MarketScan commercial and Medicare supplemental databases to identify patients aged 18 years or older with a diagnosis of HFpEF and initiation of SAC/VAL (2015-2020) or ARB (2009-2014) therapy. The index date was the date of the first SAC/VAL or ARB prescription fill. After propensity score (PS) matching with a ratio of 1 up to 3, Cox proportional hazards regression was used with robust variance estimators to compare the risks of HF-related hospitalization and all-cause hospitalization between the 2 therapies. Several subgroup and sensitivity analyses were conducted to check the robustness of the main analysis. RESULTS: After PS matching, 2,520 patients (846 receiving SAC/VAL and 1,674 receiving an ARB) were included in the final analyses. After controlling for covariates, there was no difference in the risk of HF-related hospitalization between SAC/VAL and ARB recipients (adjusted hazard ratio [aHR], 1.33; 95% confidence interval [CI], 0.99-1.77). There was also no difference in the risk of all-cause hospitalization between SAC/VAL and ARB recipients (aHR, 1.06; 95% CI, 0.91-1.24). CONCLUSION: Among individuals with private or Medicare Advantage insurance plans, there was no significant difference in the risk of HF-related hospitalization or all-cause hospitalization between adults with HFpEF who received SAC/VAL and those who received ARB therapy.
American Journal of Cardiovascular Drugs · 2024-04-30 · 4 citations
articleResearch in Social and Administrative Pharmacy · 2023-01-06 · 6 citations
articleValue in Health · 2023-06-01
articleOpen accessValue in Health · 2023-06-01
articleJournal of Managed Care & Specialty Pharmacy · 2023-10-27 · 5 citations
articleOpen accessThis research was supported by the BMS/Pfizer Alliance American Thrombosis Investigator Initiated Research Program. The funding source had no role in the design, collection, analysis, or interpretation of the data or the decision to submit the article for publication. Dr Lo-Ciganic reported receiving research funding from Merck Sharp & Dohme Corp. Dr Dietrich reported receiving honorarium for training and education from BMS/Pfizer. Dr DeRemer is a stockholder of Portola Pharmaceuticals and reported receiving personal fees for advisory board meeting from BMS. No other disclosures were reported.
Frequent coauthors
- 31 shared
Haesuk Park
University of Florida
- 29 shared
Christina E. DeRemer
University of Florida
- 25 shared
Steven M. Smith
University of Florida
- 21 shared
Kyle A. Davis
- 19 shared
Wei‐Hsuan Lo‐Ciganic
University of Pittsburgh
- 16 shared
John G. Gums
University of Florida
- 14 shared
James R. Taylor
University of the West of Scotland
- 13 shared
David M. Quillen
University of Florida
Awards & honors
- Member of American Academy of Professional Coders (2016-curr…
- Member of American College of Clinical Pharmacy (2011-curren…
- Certified Evaluation and Management Coder (CEMC) (2018)
- Certified Professional Coder (CDC) (2016)
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Eric A Dietrich
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup